Schubert & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Schubert & Co’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-57	Closed	-$5.54K	–	232
2023 Q1	$5.54K	Buy	57 +1	+2%	+$104	﹤0.01%	409
2022 Q4	$5.79K	Sell	56 -17	-23%	-$1.6K	0.01%	384
2022 Q3	$6K	Buy	73 +34	+87%	+$3.03K	0.01%	316
2022 Q2	$3K	Buy	39 +23	+144%	+$1.83K	﹤0.01%	538
2022 Q1	$1K	Buy	16 +4	+33%	+$335	﹤0.01%	595
2021 Q4	$1K	Buy	+12	New	+$990	﹤0.01%	542

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Schubert & Co's BMRN Position: Q2 2023 in Review

Schubert & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 57 shares — an estimated $5.54K sold.

Schubert & Co first reported a position in BMRN in Q4 2021 and held it in 6 quarters. The position peaked at $6K in Q3 2022. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Schubert & Co reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 57 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $5.54K.
Schubert & Co first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 6 quarters.
Schubert & Co's BioMarin Pharmaceuticals position peaked at $6K in Q3 2022.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.